Kura Oncology (NASDAQ:KURA) Trading Up 10.7% - Should You Buy?

Key Points

• Kura Oncology's share price increased by 10.7% to $6.13 during mid-day trading, with a volume decline of 26% compared to its average daily trading volume.
• Analysts have varying ratings on Kura stock, with one sell rating, three hold ratings, ten buy ratings, and one strong buy rating; the average consensus target price is $24.10.
• The company reported a quarterly EPS loss of ($0.75), significantly missing the consensus estimate, with revenue totaling $15.29 million against expectations of $64.95 million.

Kura Oncology, Inc. (NASDAQ:KURA - Get Free Report) was up 10.7% on Tuesday . The company traded as high as $6.14 and last traded at $6.13. Approximately 1,042,676 shares traded hands during trading, a decline of 26% from the average daily volume of 1,403,088 shares. The stock had previously closed at $5.54.

Analysts Set New Price Targets

KURA has been the subject of a number of recent research reports. Wedbush restated an "outperform" rating and issued a $36.00 target price on shares of Kura Oncology in a research report on Friday, June 20th. Mizuho lowered their price objective on shares of Kura Oncology from $32.00 to $30.00 and set an "outperform" rating for the company in a report on Monday, May 19th. Wall Street Zen raised shares of Kura Oncology from a "sell" rating to a "hold" rating in a research note on Sunday. Barclays reduced their target price on shares of Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a report on Friday, May 2nd. Finally, JMP Securities lowered their price target on shares of Kura Oncology from $28.00 to $24.00 and set a "market outperform" rating for the company in a research note on Monday, August 11th. Four analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $24.10.

Kura Oncology Stock Up 11.2%

The firm has a market cap of $637.11 million, a PE ratio of -3.25 and a beta of 0.41. The company has a debt-to-equity ratio of 0.02, a quick ratio of 6.16 and a current ratio of 6.16. The company's 50-day simple moving average is $6.20 and its two-hundred day simple moving average is $6.63.

Kura Oncology (NASDAQ:KURA - Get Free Report) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.75) EPS for the quarter, missing the consensus estimate of $0.15 by ($0.90). The firm had revenue of $15.29 million for the quarter, compared to analysts' expectations of $64.95 million. On average, analysts predict that Kura Oncology, Inc. will post -2.44 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Kura Oncology

Several institutional investors and hedge funds have recently bought and sold shares of KURA. E Fund Management Co. Ltd. increased its position in shares of Kura Oncology by 18.9% during the first quarter. E Fund Management Co. Ltd. now owns 12,252 shares of the company's stock valued at $81,000 after buying an additional 1,951 shares during the period. MetLife Investment Management LLC boosted its position in Kura Oncology by 6.6% during the 4th quarter. MetLife Investment Management LLC now owns 44,828 shares of the company's stock valued at $390,000 after acquiring an additional 2,776 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Kura Oncology by 10.9% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 30,273 shares of the company's stock worth $175,000 after acquiring an additional 2,976 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Kura Oncology by 6.3% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 50,008 shares of the company's stock worth $333,000 after acquiring an additional 2,977 shares during the period. Finally, Virtus ETF Advisers LLC raised its position in shares of Kura Oncology by 71.6% in the 4th quarter. Virtus ETF Advisers LLC now owns 7,336 shares of the company's stock worth $64,000 after acquiring an additional 3,061 shares in the last quarter.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.